Buy GLP-3R Lipidated Research Peptide | Koi Aminos
KOIAMINOS
3rd PartyLab Tested
COAVerified
GMPAligned
GLP-3 R research peptide
Lyophilized powder

GLP-3 R Lipidated Triple Agonist Research Peptide

Lipidated Triple Agonist · GLP-1R / GIPR / GCGR

GLP-3R is the lipidated variant - a 39-amino-acid GLP-1R/GIPR/GCGR triagonist with a fatty acid conjugate that extends half-life and alters receptor-binding kinetics vs. unlipidated analogs.

Size: 10mg

$89.95/ 10mg≥98% HPLC
Buy Now on Koi Peptides - $89.95

3rd Party

Lab Tested

Fast 2–5

Day Shipping

COA

Publicly Available

For Research Use Only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively for laboratory and analytical research purposes.

Molecular Weight

4845.44 g/mol

Unlipidated triple agonists have a half-life ceiling. For extended-duration assays, pharmacokinetic modeling, or any protocol where clearance rate matters, a lipidated analog is the right tool. GLP-3R solves exactly that problem.

It is a lipidated 39-amino-acid triagonist (MW 4845.44 g/mol, formula C221H342N46O68) activating GLP-1R, GIPR, and GCGR simultaneously. Its proprietary fatty acid conjugate and sequence modifications extend plasma half-life and preserve receptor-binding fidelity across all three targets - making it structurally distinct from unlipidated analogs like GLP-3 RT (Retatrutide).

We supply GLP-3R at ≥98% HPLC purity as lyophilized powder with a lot-specific COA. 10mg, 20mg, 30mg, and 60mg vials. For direct comparison against the unlipidated sequence, see GLP-3 RT. For in vitro laboratory research use only.

Key Takeaways

→Lipidated triagonist: fatty acid conjugate extends half-life vs. GLP-3 RT - the right tool for pharmacokinetic modeling and longer-duration assays
→MW 4845.44 g/mol (C221H342N46O68) - 114 Da heavier than Retatrutide, directly reflecting the lipidation addition
→Direct structural comparator to GLP-3 RT: order both for lipidation strategy and receptor-binding kinetics research
→≥98% HPLC purity; lot-specific COA with LC-MS identity confirmation
→Same four sizes as GLP-3 RT: 10mg, 20mg, 30mg, 60mg - side-by-side dosing protocols

Key Scientific Specifications

Lipidated 39-amino-acid triple agonist: simultaneous GLP-1R, GIPR, and GCGR activation
Molecular formula: C221H342N46O68 · MW: 4845.44 g/mol (114 Da heavier than unlipidated GLP-3 RT)
Proprietary fatty acid conjugate and sequence modifications for extended half-life and receptor-binding fidelity
≥98% purity by HPLC/MS; supplied as lyophilized acetate salt; lot-specific COA with LC-MS identity
GMP-aligned synthesis; suitable for triple-agonist, receptor crosstalk, conjugation strategy, and metabolic research

Research-Referenced Attributes

Based on published preclinical and clinical literature; not therapeutic claims. For laboratory research use only.

Lipidation strategy research: half-life extension via fatty acid conjugation compared to unlipidated GLP-3 RT (Retatrutide) in side-by-side receptor pharmacology studies
Triple receptor agonism (GLP-1R + GIPR + GCGR) - synergistic receptor crosstalk, distinct from semaglutide (GLP-1R) and tirzepatide-class compounds (GLP-1R + GIPR)
Pharmacokinetic half-life modeling for lipidated vs. unlipidated peptide analogs in the triple-agonist class
Structural integrity and degradation kinetics analysis for extended-half-life lipidated peptide research
Comparative receptor binding: lipidated vs. unlipidated triple-agonist receptor selectivity profiles across GLP-1R, GIPR, and GCGR
Metabolic dysfunction, hepatic steatosis, glycemic regulation, and cardiovascular outcome research models

Also in This Research Area

Researchers working with GLP-3 R frequently also order GLP-3 RT for triple-agonist receptor activation research, and GLP-2 TZ dual agonist for incretin pharmacology comparison. Both are available as lyophilized research-grade peptides on the Koi Aminos research peptide marketplace.

Related Compounds

GLP-3 RT

GLP-3 RT

Single and dual GLP-1 agonists leave GCGR activation on the table. GLP-3 RT (Retatrutide) hits all three - GLP-1R, GIPR, and GCGR - the only way to model true triple-receptor crosstalk.

$89.95–$449.95View
GLP-2 TZ

GLP-2 TZ

GLP-2 TZ is the dual-agonist bridge in the GLP-1 class - it hits GIP and GLP-1 receptors simultaneously, positioning between semaglutide (GLP-1R only) and GLP-3 RT (GLP-1R + GIPR + GCGR).

$89.95–$239.95View